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Despite the need for more effective treatments for psychiatric disorders, development of new medications
has stalled. Here we discuss the promise of personalized medicine in developing more efficacious and
individualized pharmacotherapies that take into account genetic variation and target groups of patients
who share biology, not just symptoms.Introduction: Pharmacogenomics,
Pharmacogenetics, and
‘‘Personalized Medicine’’
Medication development formental disor-
ders has stalled over the past three
decades. After the serendipitous dis-
covery of antipsychotic and antidepres-
sant medications in the 1950s and
1960s, and the development of more
selective and better tolerated compounds
in the 1970s and 1980s, the field has come
to rely on ‘‘me-too’’ compounds and
aggressive marketing. This approach has
led to robust sales of medication but little
evidence of greater efficacy. One excep-
tion is the development of clozapine, an
antipsychotic that appears more effective
than other compounds but is underpre-
scribed because of rare adverse hema-
tologic events. Recently, many major
pharmaceutical companies have all but
abandoned drug discovery efforts for
mental illness. We may have left behind
the era of blockbuster drugs designed to
treat large segments of the population.
We now need to identify new drug targets
and refocus our drug discovery efforts to
search—as Munos (2009) put it—for
breakthroughs rather than blockbusters.
The need for better treatments is unde-
niable. Mental illness is now the leading
cause of healthy life lost in the developed
world and is rising rapidly in developing
countries (WHO,2006; http://www.who.int/
mental_health/management/depression/
definition/en). Existing antipsychotics fail
to address the cognitive symptoms of
schizophrenia, such as executive dysfunc-
tion, which have been increasingly recog-
nized as highly disabling (Hyman andFenton, 2003). Available antidepressants
act slowly and still fail to bring about remis-
sion in more than half of patients with
depression. Lithium remains highly effec-
tive for some people with bipolar disorder,
but most do not enjoy sufficient benefit
from lithium or a range of more recently
developedmood stabilizers. Posttraumatic
stress disorder (PTSD) and other combat-
relatedmental illnesses have reachedcrisis
levels among recent veterans, and yet no
medication has proven effective. Suicide,
usually related to mental illness, is a major
causeof death, with a rate that is now twice
the homicide rate and even surpasses
traffic fatalities in the U.S. (Centers for Dis-
ease Control; http://www.cdc.gov/nchs/
data/nvsr/nvsr60/nvsr60_04.pdf).
The key lesson of the past decade
of clinical trials is the heterogeneity of
psychiatric diagnoses. Diagnostic cate-
gories, suchasschizophrenia, depression,
or autism, though each defined by a
broader set of observed symptoms, may
individually comprise different biological
entities with distinct pathophysiologies,
requiring different treatments. What we
need now are medications for targeted
subgroups of patients within diagnostic
categories who share biology, not just
symptoms. This is the essence of person-
alized medicine or what has recently
been called ‘‘precision medicine’’ (Com-
mittee on a Framework for Developing a
NewTaxonomyofDisease, 2011). Person-
alized medicine overlaps (Figure 1) with
what is coming to be known as ‘‘genomic
medicine,’’ which uses information from a
patient’s genome for diagnosis, progno-
sis, and treatment planning, emphasizingNeurouncommon or unique aspects of each
patient (for review, see Feero et al., 2010).
Emphasis on the unique aspects of a
patient is, in fact, nothing new for psychi-
atry. Effective psychiatric care has always
been challenging, in part, precisely be-
cause it has always been personalized.
Every unhappy family may indeed be un-
happy in its own way. That is why we need
a much larger variety of treatments, each
with amuch narrower range of indications.
Some Pharmacogenomic ‘‘Home
Runs’’
Traditional pharmacogenetics and geno-
mics are forerunners of genomicmedicine
that use genetic methods to better
match patients with treatments. The focus
is on genetic markers that correlate with
treatment response or adverse events.
Unlike clinical trials, which emphasize
homogeneity of outcomes, pharmacoge-
netic studies emphasize heterogeneity.
As such, the goal is to maximize efficacy
while minimizing adverse events. Genetic
variation can affect how individuals handle
medications in a variety of ways, ranging
from absorption to toxicity, all in the
context of other individual variables, such
as treatment adherence (Figure 2).Despite
this complexity, several pharmacogenetic
success stories have emerged in recent
years. A few are highlighted here to illus-
trate how genetics can help to reduce
toxicity and adverse events—traditional
aims of pharmacogenomics—but also
help to identify subgroups of patients
with distinct pathophysiology that may
be uniquely responsive to particular
medications.n 74, June 7, 2012 ª2012 Elsevier Inc. 773
Figure 1. The Nested Relationship between Personalized Medicine,
Genomic Medicine, and Pharmacogenetics and Genomics
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Polymorphisms
A set of common genetic
variants accounts for up
to 40% of the variance in
optimal dosage of warfarin,
a common anticoagulant (for
review, see Carlquist and An-
derson, 2011). This discovery
has garnered much atten-
tion, because bleeding com-
plications from warfarin are
not rare and can be serious.
In 2010, the FDA revised
warfarin labeling to include
dosage guidelines based on
genotype—a first. However,
it is not yet clear that the
genetic tests bring additional
clinical utility beyond what
can be done by skillful moni-
toring of standard blood clott-
ing assays, such as the INR.
HLA Marker of Stevens
Johnson Syndrome with
CarbamazepineStevens Johnson syndrome (SJS) is a rare
but serious inflammatory disorder of the
skin that occurs in a variety of settings
but has long been associated with expo-
sure to anticonvulsants such as lamotri-
gine, carbamazepine, and phenytoin. In
2004, Chung et al. (2004) reported that
patients of Han Chinese ancestry who
developed SJS after exposure to carba-
mazepine were substantially more likely
to carry the human leukocyte antigen
(HLA) haplotype HLA-B*1502, which is
common in persons of Asian ancestry.
This finding has been confirmed in other
Asian populations, but not in non-Asians,
in whom HLA-B*1502 is rare.
Recently, the U.S. Food and Drug
Administration changed the carbamaze-
pine labeling to highlight the potential
value of HLA testing in patients of Asian
ancestry being considered for carbama-
zepine treatment. This is an example of a
strong genetic marker for a rare but
serious adverse event. The clinical utility
in patients of Asian ancestry seems clear,
although it is not yet clear whether HLA-
B*1502 screening is being widely adopted
into clinical practice.
Ivacaftor Treatment for Uncommon
Form of Cystic Fibrosis
Cystic fibrosis (CF) was one of the first
diseases whose causative gene, CFTR,774 Neuron 74, June 7, 2012 ª2012 Elsevier Inc.was identified by human genetic mapp-
ing. Subsequent work over two decades
revealed that each of the disease muta-
tions in CFTR affects the protein differ-
ently, making corrective therapy very
challenging. A small-molecule screening
approach identified a compound that
partially corrected the defect caused by
the G551D mutation, present in about
4% of patients with CF. A version of
this compound, known as ivacaftor, was
later shown to improve health and lung
function in patients over 5 years of age
who received the drug over 48 weeks
(Ramsey et al., 2011). Ivacaftor has not
yet been shown to affect survival in
G551D carriers and apparently has no
benefit for the majority of CF patients,
who carry other mutations. Despite these
limitations, ivacaftor is one of the first
examples of an effective treatment that
targets patients carrying a particular
disease mutation.
How Can This Work in
Neuropsychiatry?
Pharmacogenomic studies have been
underway for several years in neuro-
psychiatry, yet the field still seems in its
infancy. Many early studies suffered
from a lack of large study cohorts and
high-throughput molecular technology,which only became available
relatively recently. More
recent studies have gener-
ated promising leads, but
effect sizes remain small and
replication studies in large
samples are generally
lacking.
Cytochrome P450
Most drugs are at least partly
metabolized by the cyto-
chrome P450 (CYP) system,
a family of enzymes that
seems to have evolved to
help cope with environmental
toxins. Variation in the genes
encoding the cytochrome en-
zymes is extensive and has
long been known to affect
metabolism of certain drugs,
including psychotropics like
olanzepine, sertraline, and
several benzodiazepines. For
these reasons, the CYP
genes have been extensively
studied in psychiatry and agene chip that captures most of the rele-
vant functional variation is being
promoted for use in the field (for review,
see Black et al., 2007). So far, however,
the clinical utility of such testing has not
been proven for most patients (Evaluation
of Genomic Applications in Practice and
Prevention [EGAPP] Working Group,
2007).
Candidate Gene and Genome-wide
Association Studies of
Antidepressant Outcome
Several candidate gene association
studies have been carried out in recent
years and have identified some promis-
ing markers of antidepressant outcome.
Numerous studies have implicated
SLC6A4 variation in antidepressant treat-
ment outcome, although the outcome
phenotypes have varied substantially
and a recent meta-analysis found no
overall effect (Taylor et al., 2010). Other
promising leads include the following:
FKBP5, which encodes a protein involved
in glucocorticoid trafficking (Binder et al.,
2004); HTR2A, which encodes the sero-
tonin 2A receptor (McMahon et al., 2006);
and ABCB1, which encodes a p-glyco-
protein that affects brain concentrations
of some antidepressants (Uhr et al.,
2008). All of these findings await robust
replication in large samples.
Figure 2. Approaches to the Pharmacogenomics of Psychotropic
Medications
Individual variation reflects both genetic and nongenetic factors that converge
on the absorption, distribution, central target, metabolism, and toxicity of
medications.
Neuron
NeuroViewIdentification of
Treatment-Responsive
Subgroups
Most of the common neu-
ropsychiatric disorders prob-
ably represent a collection of
less common—even rare—
diseases. We need to begin
to think in terms of ‘‘lithium-
responsive mood disorder’’
or ‘‘clozapine-responsivepsy-
chotic disorder.’’ Such treat-
ment-responsive subgroups
may share specific genes or
other characteristics. Each of
the current diagnostic cate-
gories may actually encom-
pass several subgroups for
which a new treatment needs
to be designed, as under-
scored by the example of iva-
caftor in CFTR therapy sum-marized above. Autism, which is likely a
polygenic disorder, may serve as a good
model in developing treatment strategies
in the broader realm of neuropsychiatry.
Recent work has identified several geno-
mic anomalies associated with autism (re-
viewed inMalhotra andSebat, 2012). Each
genetic alteration may therefore implicate
a distinct molecular etiology, and hence
a different potentially ‘‘druggable’’ molec-
ular target. Depending on the underlying
molecular or neural substrates, which
may differ evenwithin the same diagnostic
classification, effective treatment may
require cognitive or behavioral treat-
ments rather than medications. Most may
require both.
Identification of Patients at High
Risk for Severe Adverse Events
As exemplified by SJS during carbamaze-
pine treatment, we need to identify good
predictive markers of severe adverse
events arising during psychopharmaco-
logic treatment. Such markers could
enable much wider use of drugs such as
clozapine that offer distinct advantages to
the majority of patients, while preventing
exposure of those at high risk for severe
events. Recent suggestive data on geno-
mic predictors of metabolic syndrome
may be an early example of this approach
(reviewed in Chowdhury et al., 2011).
Key Challenges
Discovery requires large patient groups.
The large number of hypotheses testedin a typical genome-wide experiment
poses a substantial multiple-testing prob-
lem. Patients who suffer rare adverse
events may not be represented in small
clinical trials. Treatment-responsive sub-
groups may comprise only a minority of
patients grouped by current diagnostic
categories. Such problems can be over-
come with large sample sizes, but these
can be expensive to collect and study.
The STAR*D, CATIE, and STEP*BD
projects were the first to provide samples
large enough for genome-wide searches.
Each of these studies collected a large
group of patients with a common diag-
nosis (major depression, schizophrenia,
and bipolar disorder, respectively) and
assessed outcomes prospectively after
relatively standardized treatment with
one or more established psychotropic
agents. These studies were not designed
as pharmacogenetic studies but did
collect DNA on many participants, thus
enabling later pharmacogenetic studies
that would not have otherwise been
possible. We now need additional large
samples. One approach might be to
aggregate samples from the large num-
bers of ongoing clinical trials, as dis-
cussed further below.
Clinical and Genetic Sources
of Heterogeneity
Even the most valuable pharmacoge-
netic markers never tell the whole story.
Treatment outcomes are always the result
of a complex interplay of individual,Neuron 74, June 7,social, and stochastic fac-
tors. In psychiatry, adherence
is a serious and often over-
looked problem. For complex
disorders, the best treat-
ment would be one that
uniquely corrects a specific
molecular defect. This is
being achieved for occa-
sional patients with rare dis-
eases, such as dopa-respon-
sive dystonia (Bainbridge
et al., 2011), but remains
a major challenge, especially
for neuropsychiatry.
Demonstrating Clinical
Utility
The initial discovery phases
of pharmacogenetic studies
typically emphasize statistical
significance and replication.
These yardsticks are neces-sary for establishing the scientific reli-
ability of a finding but tell us nothing about
how valuable the information is for clinical
decision making. Here, the well-estab-
lished concept of ‘‘Number Needed to
Screen’’ is valuable, because it incorpo-
rates both the frequency of a marker and
the magnitude of its effect (Rembold,
1998). The NNS captures how many
patients need to receive a test for every
patient whose outcome is altered. Smaller
NNS values are generally better, but there
is no single threshold. If the goal is to avoid
a severe adverse event, larger NNS might
be reasonable, while quantitative impro-
vements in responsemight require smaller
NNS values to make sense clinically.
Physician Education
The interpretation of genetic information
is a new challenge for most physicians.
Because the clinical utility of pharmaco-
genetic markers typically is probabilistic,
increasing the odds of one outcome
versus another, it is not always clear
how best to use this information in clinical
decision making (Khoury et al., 2010). As
genetic information becomes more com-
prehensive, the competing odds become
more difficult to judge. This will require
a kind of actuarial decision making that
is unfamiliar to many clinicians. Medical
school curricula are becoming more
genetically informed, but reaching resi-
dents and practicing physicians in ways
that can alter their clinical practice is
challenging (Winner et al., 2010).2012 ª2012 Elsevier Inc. 775
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Ultimately, better medications will follow
from a better understanding of the biology
of psychiatric disorders. This may take
years, but there are several steps that
can be taken now to make better use of
what we already know and to position
the field to capitalize quickly on new bio-
logic insights, whenever they arise.
DNA Collection in Clinical Trials
We have already explained why genetic
discoveries require large samples, but
these can be slow and expensive to col-
lect. Volunteers in ongoing clinical trials
offer an attractive alternative. Although
they represent a heterogeneous group in
terms of ascertainment, diagnosis, and
treatments employed, the many ongoing
clinical trials may collectively constitute
a reasonably representative sample of
the population, well-suited to large-scale
genetic studies. We need a coordinated
effort by academia, industry, and govern-
ment to begin collecting DNA in clinical
trials and to send the samples and associ-
ated data—in anonymous form—to a
central repository, where they can be
used to fuel future large-scale studies.
Revisiting Underused Drugs that
May Be Safe and Effective in
Particular Groups
The pharmacopeia is full of drugs that
seem to have outlived their usefulness or
never found wide application: long-used
medications known to be safe that have
been superseded by drugs that are
considered more efficacious; newer
drugs that, while highly effective, were
found to cause severe adverse events in
some people. By use of genetic methods,
it may be possible to ‘‘repurpose’’ some
of thesemedications for other indications.
If good genetic markers of safety and
efficacy can be established, such re-
purposed drugs could be helpful for tar-
geted populations, in which acceptable
risk:benefit ratios can be more easily
achieved. Systematic efforts along these
lines are now being initiated in the
National Center for Advancing Transla-
tional Sciences (NCATS). NCATS is
a new component of the NIH that aims
to catalyze the generation of innovative
methods and technologies to enhance
the development, testing, and implemen-
tation of diagnostic tests and therapeutic
agents across a wide range of human ills
(http://www.ncats.nih.gov).776 Neuron 74, June 7, 2012 ª2012 ElsevierPharmacogenomics for Identifying
New Drug Targets
Traditional drug development pipelines
are inefficient and expensive. Innovative
strategies are needed, but innovation
requires new perspectives. Genetics is
providing some of these new perspec-
tives. Genome-wide association studies
have revealed a spectrum of common
genetic markers for a number of traits,
diseases, and treatment outcomes. At
about the same time, a whole new class
of genetic variation was discovered,
known as copy number variants (CNVs):
deletions and insertions of small chromo-
somal segments, containing from one to
dozens of genes. CNVs have been shown
to play a major role in autism, schizo-
phrenia, and developmental disorders
and may also contribute to treatment
outcomes (for review, see Malhotra
and Sebat, 2012). CNVs often arise de
novo as chromosomes are passed from
parent to offspring, providing a dynamic
source of genetic differences within every
generation.
Large-scale sequencing of the genome
is providing another new perspective.
Thanks to this new technology, we now
know that the average person harbors
about 10,000 mutations that directly
affect protein expression or structure,
some 200 of which amount to total gene
‘‘knockouts’’ (MacArthur et al., 2012).
We can only speculate how big a role
such dramatic variation will play in future
pharmacogenomics findings—but it will
probably be large.
Genetics is not the whole answer
but offers a solid starting point. Further
knowledge of the basic disease pro-
cesses at the cellular and molecular
level will be required to discover ideal,
curative treatments for most patients
with neuropsychiatric disorders, but
much could be achieved by personaliz-
ing the existing pharmacopeia. Personal-
ized medicine will bring new insights,
more treatment options, and better out-
comes to what psychiatrists have always
strived for—caring for each patient as an
individual.ACKNOWLEDGMENTS
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